GB2088868A

GB2088868A - Novel compounds and hapten-immunoglobulin conjugates derived from them

Info

Publication number: GB2088868A
Application number: GB8136472A
Authority: GB
Original assignee: Lilly Industries Ltd
Current assignee: Lilly Industries Ltd
Priority date: 1980-12-04
Filing date: 1981-12-03
Publication date: 1982-06-16
Also published as: ATE8255T1; US4442032A; JPH022879B2; JPS57126467A; GB2088868B; DE3164612D1; EP0053915A1; EP0053915B1; US4482484A

Abstract

Compounds of formula (I) <IMAGE> (I) in which n is 1 or 2, R1 is C1-4 alkyl, C1-4 alkoxy, nitro, amino, halo or hydroxy, m is 0, 1 or 2, R2 is an immunogenic determinant and x is 1 or 2, provided that when n is 1, x is 1 or 2 and there is one diazo moiety at the 3-position or two diazo moieties at the 3- and 5-positions, with respect to the isothiocyanate group, and the hydroxy group is at the 4-position; and provided that when n is 2, x is 1 and the diazo moiety is at the 4-position and the hydroxy groups are at the 3- and 5-positions, are described. The compounds are useful in the preparation of immunoglobulin conjugates for employment in diagnostic techniques.

Description

1

GB 2 088 868 A 1

SPECIFICATION

Novel Compounds and Hapten-Immunoglobulin Conjugates Derived From Them

This invention relates to novel compounds and their use in the preparation of novel hapten-immunoglobulic conjugates.

5 Techniques of studying antigen distribution in cell and tissue section preparations for the purpose of diagnosis are well known. Antibodies suitably marked with, for example, fluoroescent material bind to antigen on the cell surface which is thus conveniently labelled. In one technique by indirect labelling, a second-layer antibody coupled to a suitable marker is employed to label a first-layer antibody specific for a particular antigen. The first-layer antibody can be modified by covalent linkage with one or more 10 hapten molecules to form a hapten-antibody conjugate which in turn is detected by labelled antihapten antibody, see review by Wofsy L., Henry C and Cammisuli S. in Contemp. Top. Mol. Immunol. 7, 215. Such a labelling technique can also be applied to other immunoglobulin materials which may find utility in assay and control experiments.

In preparing the hapten-immunoglobulin conjugate it is, of course, important that the antibody or 15 other immunoglogulin material, should not be seriously damaged and attachment of hapten is best effected by means of a reagent consisting of a hapten linked to a suitable coupling group.

The present invention provides a novel reagent which is conveniently prepared and readily handled and which can be employed under mild conditions to prepare hapten-immunoglobulin conjugates without appreciable loss of utility. The reagent of the inventivn is a compound of the formula (I)

25

30

(HO)

20

N - N

(I)

I

(CH2)2CO2H

10

15

20

in which n is 1 or 2, R1 is C,_4 alkyl, C,_4 alkoxy, nitro, amino, halo or hydroxy, m is 0, 1 or 2, R2 is an immunogenic determinant and x is 1 or 2; provided that when n is 1, x is 1 or 2 and there is one diazo moiety at the 3-position or two diazo moieties at the 3- and 5-positions, with respect to the isothiocyanate group, and the hydroxy group is at the 4-position; and provided that when n is 2, x is 1 and the diazo moiety is at the 4-position and the hydroxy groups are at the 3- and 5-positions. The compounds of the invention are thus mono or bis azo derivatives of 4-hydroxy or 3,5-dihydroxy-phenylisothiocyanate.

In the above formula (I), R2 can be any suitable immunogenic determinant optionally in its various optical or racemic forms, and for example includes an arsonate group (—As03H2), a sulphonate group (—S03H) a nitro group (—N02), a carboxyl group (—COzH), a trimethylammonium group (Me3N—) a group derived from glutamic acid

""-conhchcc^h '

25

30

35

40

or a group derived from glycine [—C0NHCH2C02H] the preferred groups being arsonate, sulphonate and the groups derived from glutamic acid glycine. The group R1 when it is C,_4 alkyl can be straight or branched chain and can be for example methyl, ethyl, propyl, isopropyl or butyl and is preferably 35

methyl. When R1 is C,_4 alkoxy it is a C,_4 alkyl group linked via an oxygen atom to the phenyl nucleus, and is preferably methoxy. When R1 is halo it can be chloro, bromo or iodo and is preferably chloro. The most conveniently obtainable compounds are those in which m is 0 and a preferred group of compounds is one of the following formula:

40

The invention also includes a method of preparing a compound of formula 0) which comprises reacting a phenylisothiocyanate of formula

2

GB 2 088 868 A 2

10

15

20

25

30

35

40

(HD)

ICS

(II)

in which n is 1 and the hydroxy group is at the 4-position or n is 2 and the hydroxy groups are at the 3-and 5-positions, with a diazonium salt of formula

(III)

in which R1, m and R2 are as defined for formula (I) and Xs is an anion.

Reactants of formulae (II) and (III) are either known compounds or can be prepared from known compounds by simple chemical methods well known in the art For example, the starting materials of formula (III) are prepared frgm arsanilic acid, p-aminobenozyl glutamic acid, sulphanilic acid or derivatives thereof, which are readily diazotised by well recognised methods, employing for example sodium nitrite and dilute hydrochloric acid, to give the appropriate diazonium salt. The anion X® is preferably a halide ion, for example chloride.

Compounds (II) and (III) are preferably reacted together in an aqueous medium iat a temperature of from 0°C to 5°C, the pH being maintained at from 8 to 10, for example at pH 9. If desired a water miscible solvent such as dimethylformamide or tetrahydrofuran can be added, and the products of the process can be purified by recrystallisation or by gel filtration.

The compounds of the invention are convenient reagents that can be easily prepared. They are solids which are readily purified and prepared in high yield. In these respects they represent an improvement over prior art materials. Moreover they can be reacted under mild conditions with antibody to produce hapten-antibody conjugates with high yield and without significantly affecting the net charge or other physical properties of the antibody as to alter its binding activity.

The invention also provided a hapten-immunoglobulin conjugate which is an immunoglobulin modified with one or more, for example 5 to 20, groups of the formula

N = N

(IV)

10

15

20

(DH)

in which n, R1, m, R2 and x have the values defined in formula (I); and a process for preparing a hapten-immunoglobulin conjugate which comprises reacting an immunoglobulin with a compound of formula 25 (I). Preferably the immunoglobulin is an antibody.

The antibodies are obtained by well known procedures from the serum of immunised animals or by culturing hybridomas secreting monoclonal products.

Antibodies can be haptenated according to this method under mild conditions of pH and temperature with chemical modification occurring solely at free amino groups. For example the 30

reaction can be effected at a temperature of from 10°C to 25°C such as at room temperature, in a suitable aqueous medium buffered to a pH of between 7.5 to 8.6. The resulting conjugate can be purified by gel filtration and stored in saturated ammonium sulphate solution, being readily brought back into solution by dialysis employing, for examplel borate buffer or, alternatively, it can be stored in a refrigerator at 4°C or frozen at for example —20°C. 35

The reaction results in one or more molecules of formula (I) being attached to the immunoglobulin and the number of molecules attached on the conjugate depends on the concentrations of the reactants employed and the time for which the reaction is allowed to proceed. Evaluation of the conjugate can be carried out using techniques such as affinity chromatography, determination of cytotoxicity and labelling specificity. The hapten concentration in solutions of 40

conjugates can be determined by spectroscopy at pH 13, making use of pre-determined molar extraction coefficients at pH 13 of compounds of formula (I).

As has been indicated above, the hapten-antibody conjugates of the invention are employed in . conjunction with labelled antihapten antibodies. These are easy to prepare and can be purified readily

3

GB 2 088 868 A 3

by affinity chromatography (Cuatrecases and Anfinsen, Methods in Enzymology, 34,345 et seq.,

Academic Press, New York).

This system of indirect labelling can be used to discriminate between two antigens on the same cell or between two cells with distinguishing antigens. The procedure is especially suited to a situation 5 in which each of two antigens is best visualized by the indirect method, since this can be done by the 5 use of two noncrossreactive antihapten antibodies and for example antibodies with different fluorochromes can be used to distinguish clearly a variety of antigens on human and animal cell surfaces. This procedure is also suited to situations where increased sensitivity is required, by making use of the greater amplification achieved by using highly haptenised antibody.

10 Examples of preferred antibody for use in the immunoglobulin conjugates of the invention include 10 anti-human Ig, anti-human la, anti-human Leu-1, anti-human T-cell markers, and anti-mouse Thy 1,2.

The invention is illustrated by the following Examples.

Example 1

Preparation of 2-hydroxy-5-isothiocyanato-azo-benzene-4'-arsonic Acid

15 Sodium nitrite (69 mg, 1 mmole) in water (1.5 ml) was added dropwise to a cooled (<5°C) 15

solution of arsanilic acid (217 mg, 1 mmole) in 1/V HCI (2.5 ml) and the mixture stirred at <5°Cfor 30 minutes.

0.34/W borate buffer, pH 9.3 (10 ml) was added to a solution of p-hydroxyphenylisothiocyanate (151 mg, 1 mmole) in DMF (2 ml) and the resulting emulsion cooled to 5°C. The diazonium solution 20 was added dropwise with stirring at <5°C over 5 minutes, the pH being maintained at pH 9±0.2 by the 20 addition of <5/V NaOH. The reaction mixture was stirred at room temperature for 1 hour, then washed with ether (2x20 ml) and acidified to pH 1. The precipitated crude product was washed with 1 N HCI (20 ml) and water (20 ml), and redissolved in 0.1M borate buffer pH 8.6 (5 ml). This solution was chromatographed at 4°C on a 1.5x112 cm (200 ml) column of Bio-Gel P-2) (100—200 mesh) 25 equilibrated with QAM borate buffer pH 8.6. Fractions (8 ml) were collected and assessed by 600— 25 400 nm scans of aliquots diluted 1:30 with water. Fractions 17—24 were combined and acidified (pH-1), and the precipitated product washed with water (2x15 ml), suspended in water and freeze dried. X max (0.1/V NaOH) 505 nm (8900) (m.p. >260°C).

The following compounds were similarly prepared 30 2-hydroxy-5-isothiocyanato-azo-benzene-4'-sulphonic acid (from sulphanilic acid), A max (0.1 N 30 NaOH) 510 nm (e 9100) (m.p. >260°C).

L-2-(2-hydroxy-5-isothiocyanato-azo-benzene-4'-carboxamido)glutaric acid (from L-p-aminobenzoylglutamic acid), A max (0.1/V NaOH) 510 nm (e 10900) (m.p. 98°C).

Example 2

35 Preparation of L-benzoyl-glutamic Acid-conjugated Mouse lgG2 Anti-human la 35

100 fi\ of a solution of L-2-(2-hydroxy-5-isothiocyanato-azo-benzene-4'-carboxamido)-glutaric acid (4 mg/ml 0.34M borate buffer pH 8.6) was added to a solution of mouse lgG2 anti-human la (2.8 mg) in the same buffer (0.4 ml). The mixture was stored in the dark at room temperature for 18 hours.

then chromatographed on a 1.0x16.5 cm (13 ml) column of Biogel P-6 (supplied by Bio-Rad 40 Laboratories Limited) equilibrated with buffer. The excluded peak (2.4 ml) was collected, and contained 40 1.2 mg/ml of conjugate having 8.2 moles L-benzoylglutamic acid/mole of antibody.

Example 3

Preparation of Arsanilic Acid-conjugated Mouse IgG, Anti-carcino-embryonic Antigen

120 fiI of a solution of 2-hydroxy-5-isothiocyanato-azo-benzene-4'-arsonic acid (4 mg/ml 0.3AM 45 borate buffer pH 8.6) was added to a solution of mouse IgG, anti-carcinoembryonic antigen (4 mg) in 45 the same buffer (0.5 ml). The mixture was stirred in the dark at room temperature. After 6 hours a 0.25 ml aliquot was chromatographed on a 1.0x15.5 cm (12 ml) column of Ultrogel AcA-54 (LKB Instruments Ltd.) equilibrated with buffer. The excluded peak (2.8 ml) was collected and containe 0.6 mg/ml of conjugate having 8.8 moles arsanilic acid/mole of antibody.

50 After 24 hours the remainder of the reaction mixture was similarly chromatographed. The 50

excluded peak (3.4 ml) contained 0.6 mg/ml of conjugate having 15.2 moles arsanilic acid/mole of antibody.

4

GB 2 088 868 A 4

10

15

Claims

1. A compound of formula

(HO)

N - N

(I)

_J DC

in which n is 1 or 2, R1 is C.,_4 alkyl, Cn_4 alkoxy, nitro, amino, halo or hydroxy, m is 0,1 or 2, R2 is an immunogenic determinant and x is 1 or 2, provided that when n is 1, x is 1 or 2 and there is one diazo moiety at the 3-position or two diazo moieties at the 3- and 5-positions, with respect to the isothiocyanate group, and the hydroxy group is at the 4-position; and provided that when n is 2, x is 1 and the diazo moiety is at the 4-position and the hydroxy groups are at the 3- and 5-positions.

2. A compound according to Claim 1 in which the immunogenic determinant is an arsonate or sulphonate group or a group derived from glutamic acid.

3. A compound according to either of Claims 1 and 2 in which n is 1, x is 1 and m is 0.

4. A method of preparing a compound of formula (I) as defined in Claim 1, which comprises reacting a phenylisothiocyanate of formula

10

CHO)

NCS

(II)

20

(ill)

in which R1, m and R2 are as defined for formula (I).

5. A hapten-immunoglobulin conjugate which is an immunoglobulin modified with one or more groups of the formula

15

20

N = N

(IV)

(OH).

6. A method of preparing a hapten-immunoglobulin conjugate as defined in Claim 5 which comprises reacting an immunoglobulin with a compound as defined in Claim 1.

Printed for Her Majesty's Stationery Office by the Courier Press, Leamington Spa, 1982. Published by the Patent Office, 25 Southampton Buildings, London, WC2A 1 AY, from which copies may be obtained.